000184863 001__ 184863
000184863 005__ 20230212173541.0
000184863 0247_ $$2CORDIS$$aG:(EU-Grant)668724$$d668724
000184863 0247_ $$2CORDIS$$aG:(EU-Call)H2020-PHC-2015-two-stage$$dH2020-PHC-2015-two-stage
000184863 0247_ $$2originalID$$acorda__h2020::668724
000184863 035__ $$aG:(EU-Grant)668724
000184863 150__ $$aTools and TECHNOlogies for Breakthrough in hEArt Therapies$$y2016-01-01 - 2019-12-31
000184863 371__ $$aDASGIP INFORMATION AND PROCESS TECHNOLOGY GMBH$$bDASGIP$$dGermany$$ehttp://www.dasgip.com$$vCORDIS
000184863 371__ $$aOVIZIO IMAGING SYSTEMS$$bOVIZIO$$dBelgium$$ehttp://www.ovizio.com$$vCORDIS
000184863 371__ $$aKADIMASTEM LTD$$dIsrael$$ehttp://www.kadimastem.com$$vCORDIS
000184863 371__ $$aUniversity of Sheffield$$bUniversity of Sheffield$$dUnited Kingdom$$ehttp://www.sheffield.ac.uk/$$vCORDIS
000184863 371__ $$aHannover Medical School$$bMHH$$dGermany$$ehttp://www.mh-hannover.de/index.php?&L=1$$vCORDIS
000184863 371__ $$aPARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG$$bPMU$$dAustria$$ehttp://www.pmu.ac.at$$vCORDIS
000184863 371__ $$aACADEMISCH ZIEKENHUIS LEIDEN$$bLeiden University Medical Center$$dNetherlands$$ehttp://www.lumc.nl$$vCORDIS
000184863 371__ $$aUniversity Medical Center Utrecht$$bUMC$$dNetherlands$$ehttp://www.umcutrecht.nl/nl/$$vCORDIS
000184863 372__ $$aH2020-PHC-2015-two-stage$$s2016-01-01$$t2019-12-31
000184863 450__ $$aTECHNOBEAT$$wd$$y2016-01-01 - 2019-12-31
000184863 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000184863 680__ $$aCardiovascular diseases including myocardial infarction (MI), which entails the irreversible loss of heart muscle tissue, constitute a major socio-economic burden in global healthcare. With whole organ transplantation as the only treatment option for end-stage heart failure, MI patients could particularly benefit from advanced cell therapies aimed at the functional reconstitution of damaged hearts. Human induced pluripotent stem cells (hiPSCs) can be derived by reprogramming patients’ somatic cells. In contrast to adult (stem) cells e.g. from blood, bone marrow or the heart, hiPSCs have unlimited expandability and differentiation potential into all relevant cell types including cardiomyocytes, endothelial cells, pericytes and connective tissue-forming cells, making them highly attractive as a universal cell source for organ repair. However, technologies for the robust therapeutic scale production of hiPSC-derived progenies in line with GMP standards and at reasonable cost are currently lacking.
TECHNOBEAT’s ultimate objectives are 1) to advance therapeutic scale cell production through innovative bioreactor technologies and novel cell monitoring tools, and 2) to develop regulatory compliant bioprocessing of innovative iPSC-based cardiac µ-tissue. The clinical translation of cardiac µ-tissue will require 3) the development  and application of tools for improved cell delivery and longitudinal in vivo monitoring of cell grafts, and 4) proof-of-concept for safety and functional integration in physiologically relevant preclinical models of cellular heart repair.
Through its interdisciplinary excellence, TECHNOBEAT’s consortium of leading European stem cell researchers, clinicians, tissue-, bioprocess-, and technical- engineers in industry and academia is ideally positioned to address these ambitious objectives. It will provide new treatment options for suffering patients and increase Europe’s attractiveness as a hub for innovative medical technologies.
000184863 909CO $$ooai:juser.fz-juelich.de:282128$$pauthority$$pauthority:GRANT
000184863 909CO $$ooai:juser.fz-juelich.de:282128
000184863 970__ $$aoai:dnet:corda__h2020::ec5ae9f132f5bf22883a8fe93474b692
000184863 980__ $$aG
000184863 980__ $$aCORDIS
000184863 980__ $$aAUTHORITY